Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma is a phase 3 interventional study registered as NCT07804186, led by IDEAYA Biosciences, and recruiting on the registry. Official title: A Randomised, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma. Planned enrolment is 450 participants (estimated). The study started in 2026-09 and primary completion is expected in 2034-03. No results have been posted on ClinicalTrials.gov.